Form 4: Alnylam Executive's RSU Vesting

Alnylam Pharmaceuticals' EVP, Chief Commercial Officer, Tolga Tanguler, saw 1,666 restricted stock units vest and convert to common stock.

Summary

• Tolga Tanguler, Executive Vice President and Chief Commercial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), reported a change in beneficial ownership.
• On February 27, 2026, 1,666 restricted stock units (RSUs) vested and were released.
• These RSUs were part of an original grant of 5,000 restricted stock units made on February 27, 2023, which vest ratably over three years.
• This transaction represents the third and final tranche of the February 27, 2023 grant.
• Following the vesting, Tolga Tanguler's direct beneficial ownership of Common Stock increased to 33,435 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine and expected executive compensation transaction with no direct implications for the company's operational or financial performance.

Positives

• The vesting of restricted stock units represents a conversion of contingent equity rights into actual shares, increasing the executive's direct ownership in the company.
• This event is a standard component of executive compensation, aligning management's interests with long-term shareholder value.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the vesting of restricted stock units is a common and expected form of executive compensation across the biotechnology and pharmaceutical industries. This practice is designed to incentivize long-term performance and align the interests of executives with those of shareholders.

Comparison to Industry Standards

• Restricted stock unit grants and their ratable vesting schedules are standard compensation practices for executives in publicly traded companies, including those in the biotech sector, comparable to practices seen at companies like Moderna, Biogen, and Gilead Sciences.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine compensation event. It reinforces executive alignment with shareholder interests through equity ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled vesting of restricted stock units for an executive. It does not provide new information regarding Alnylam Pharmaceuticals' financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. The transaction reflects a standard component of executive compensation and is not indicative of any material shift in the company's fundamentals or prospects. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

ALNYLAM PHARMACEUTICALS, ALNY, Form 4, Insider Transaction, RSU Vesting, Executive Compensation, Stock Ownership